Current status of rho-associated kinases (ROCKs) in coronary atherosclerosis and vasospasm

Cardiovasc Hematol Agents Med Chem. 2009 Oct;7(4):322-30. doi: 10.2174/187152509789541891.

Abstract

Rho-kinase (ROCK) is one of the effectors of the small GTP-binding protein Rho. Accumulating evidence suggests that the Rho/ROCK system may play an important role in the pathogenesis of atherosclerosis and coronary vasospasm via its action in vascular smooth muscle cell contraction, endothelial function and the inflammatory process. Recent observations suggest that the beneficial cardiovascular effects of statins may, at least in part, derive from the inhibition of ROCKs. Fasudil is a ROCKs inhibitor which has potential benefits in coronary artery spasm and myocardial ischemia. In this review, we aim to describe the current understanding of ROCKs signaling and their roles in the pathophysiology of atherosclerosis and coronary spasm.

Publication types

  • Review

MeSH terms

  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / analogs & derivatives
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / pharmacology
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / therapeutic use
  • Coronary Artery Disease / drug therapy*
  • Coronary Vasospasm / drug therapy*
  • Humans
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use*
  • Signal Transduction / drug effects
  • rho-Associated Kinases / antagonists & inhibitors*
  • rho-Associated Kinases / metabolism

Substances

  • Protein Kinase Inhibitors
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
  • rho-Associated Kinases
  • fasudil